| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bimagrumab | LY-3985863; BYM-338 | Phase 2 Clinical | Morphosys Ag, Novartis Pharma Ag | Diabetes Mellitus, Type 2; Myositis, Inclusion Body; Obesity; Overweight; Pulmonary Disease, Chronic Obstructive; Sarcopenia | Details |
| BIIB-110 | BIIB-110; BIIB110; ALG-801 | Phase 1 Clinical | Alivegen USA Inc | Muscular Atrophy, Spinal; Muscular Diseases | Details |
| LAE-103 | LAE-103; LAE103 | Phase 1 Clinical | Laekna Therapeutics Shanghai Co Ltd | Muscular Diseases; Muscular Disorders, Atrophic; Obesity; Sarcopenia | Details |
| SSS-67 | SSS67; SSS-67 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Obesity; Overweight | Details |
| JMT-206 | JMT206; JMT-206 | Phase 1 Clinical | Shanghai Jmt-Bio Inc | Body Weight; Obesity; Overweight; Sarcopenia | Details |
| Tirzepatide/Bimagrumab | LY-900042 | Phase 1 Clinical | Eli Lilly And Company | Details |